Exploration and characterisation of the phenotypic and genetic profiles of patients with early onset schizophrenia associated with autism spectrum disorder and their first-degree relatives: a French multicentre case series study protocol (GenAuDiss)

Arnaud Fernandez, Emmanuelle Dor, Thomas Maurin, Gaelle Laure, Marie-Line Menard, Małgorzata Drozd, Francois Poinso, Barbara Bardoni, Florence Askenazy, Susanne Thümmler, Arnaud Fernandez, Emmanuelle Dor, Thomas Maurin, Gaelle Laure, Marie-Line Menard, Małgorzata Drozd, Francois Poinso, Barbara Bardoni, Florence Askenazy, Susanne Thümmler

Abstract

Introduction: Early-onset schizophrenia (EOS) is a rare and severe condition. A higher rate of neurodevelopmental abnormalities, such as intellectual or communication impairments as well as attention deficit hyperactivity disorder, is observed in EOS compared with adult-onset schizophrenia. Early signs of autism spectrum disorders (ASD) are present in about 30% of patients. Genetic abnormalities, including copy number variations, are frequent in neurodevelopmental disorders and have been associated to ASD physiopathology. Implicated genes encode proteins involved in brain development, synapses morphology and plasticity and neurogenesis. In addition, an increasing number of genetic abnormalities are shared by EOS and ASD, underlying the neurodevelopmental hypothesis of EOS.The main objective of our study is to identify disease-causing genetic mutations in a cohort of patients affected by both EOS and ASD. Special attention will be paid to genes involved in neurodevelopmental pathways.

Methods and analysis: We describe a multicentric study in a paediatric population. The study started in April 2014. Inclusion criteria are: age 7-22 years, diagnosis of EOS with comorbid ASD and IQ >50; Parents and siblings are also enrolled. We perform psychiatric assessments (Mini International Neuropsychiatric Interview, Kiddie Schedule for Affective Disorders and Schizophrenia -Present and Lifetime Version, Positive and Negative Syndrome Scale and Scale for the Assessment of Negative Symptoms) together with neurocognitive evaluations (IQ, Trail Making Test A/B and verbal fluency). Then, we study variants of the coding part of DNA (exome), using next-generation sequencing process on trio (mother, father and child). Bioinformatics tools (RVIS and PolyPhen-2) are used to prioritise disease-causing mutations in candidate genes. The inclusion period will end in November 2019.

Ethics and dissemination: The study protocol was approved by the Local Ethic Committee and by the French National Agency for Medicines and Health Products Safety. All patients signed informed consent on enrolment in the study. Results of the present study should help to unravel the molecular pathology of EOS, paving the way for an early therapeutic intervention.

Trial registration number: NCT0256552; Pre-results.

Trial registration: ClinicalTrials.gov NCT02565524.

Keywords: autism spectrum disorder; family study; genomics; next generation and whole exome sequencing.

Conflict of interest statement

Competing interests: None declared.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

References

    1. Häfner H, Nowotny B. Epidemiology of early-onset schizophrenia. Eur Arch Psychiatry Clin Neurosci 1995;245:80–92. 10.1007/BF02190734
    1. Okkels N, Vernal DL, Jensen SO, et al. . Changes in the diagnosed incidence of early onset schizophrenia over four decades. Acta Psychiatr Scand 2013;127:62–8. 10.1111/j.1600-0447.2012.01913.x
    1. Nicolson R, Rapoport JL. Childhood-onset schizophrenia: rare but worth studying. Biol Psychiatry 1999;46:1418–28. 10.1016/S0006-3223(99)00231-0
    1. Gochman P, Miller R, Rapoport JL. Childhood-onset schizophrenia: the challenge of diagnosis. Curr Psychiatry Rep 2011;13:321–2. 10.1007/s11920-011-0212-4
    1. Vourdas A, Pipe R, Corrigall R, et al. . Increased developmental deviance and premorbid dysfunction in early onset schizophrenia. Schizophr Res 2003;62(1-2):13–22. 10.1016/S0920-9964(02)00429-2
    1. Rapoport J, Chavez A, Greenstein D, et al. . Autism spectrum disorders and childhood-onset schizophrenia: clinical and biological contributions to a relation revisited. J Am Acad Child Adolesc Psychiatry 2009;48(1):10–18. 10.1097/CHI.0b013e31818b1c63
    1. Ross RG, Heinlein S, Tregellas H. High rates of comorbidity are found in childhood-onset schizophrenia. Schizophr Res 2006;88:90–5. 10.1016/j.schres.2006.07.006
    1. World health O. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. World Health Organization 1992.
    1. American psychiatric association, American psychiatric association. DSM-IV-TR: Diagnostic and statistical manual of mental disorders, text revision. Washington, DC: American Psychiatric Association, 2000:75;78–85.
    1. American Psychiatric A, et al. . Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric Pub 2013.
    1. Nicolson R, Giedd JN, Lenane M, et al. . Clinical and neurobiological correlates of cytogenetic abnormalities in childhood-onset schizophrenia. Am J Psychiatry 1999;156:1575–9. 10.1176/ajp.156.10.1575
    1. Ahn K, Gotay N, Andersen TM, et al. . High rate of disease-related copy number variations in childhood onset schizophrenia. Mol Psychiatry 2014;19:568–72. 10.1038/mp.2013.59
    1. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003;60:1187–92. 10.1001/archpsyc.60.12.1187
    1. Asarnow RF, Forsyth JK. Genetics of childhood-onset schizophrenia. Child Adolesc Psychiatr Clin N Am 2013;22:675–87. 10.1016/j.chc.2013.06.004
    1. Purcell SM, Wray NR, Stone JL, et al. . Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009;460:748–52. 10.1038/nature08185
    1. Addington AM, Gauthier J, Piton A, et al. . A novel frameshift mutation in UPF3B identified in brothers affected with childhood onset schizophrenia and autism spectrum disorders. Mol Psychiatry 2011;16:238–9. 10.1038/mp.2010.59
    1. Veltman JA, Brunner HG. De novo mutations in human genetic disease. Nat Rev Genet 2012;13:565–75. 10.1038/nrg3241
    1. Smedemark-Margulies N, Brownstein CA, Vargas S, et al. . A novel de novo mutation in ATP1A3 and childhood-onset schizophrenia. Cold Spring Harb Mol Case Stud 2016;2:a001008 10.1101/mcs.a001008
    1. Ambalavanan A, Girard SL, Ahn K, et al. . De novo variants in sporadic cases of childhood onset schizophrenia. Eur J Hum Genet 2016;24:944–8. 10.1038/ejhg.2015.218
    1. Rapoport JL, Giedd JN, Gogtay N. Neurodevelopmental model of schizophrenia: update 2012. Mol Psychiatry 2012;17:1228–38. 10.1038/mp.2012.23
    1. Kaufman J, Birmaher B, Brent D, et al. . Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997;36:980–8. 10.1097/00004583-199707000-00021
    1. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 1994;24:659–85. 10.1007/BF02172145
    1. Sheehan DV, Lecrubier Y, Sheehan KH, et al. . The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59 Suppl 20:2233.
    1. Lecrubier Y, Weiller E, Hergueta T, et al. . Mini International Neuropsychiatric Interview French Version 5.0. 0. Paris, France: INSERM, 1998.
    1. Wechsler D. WISC-IV: Wechsler Intelligence Scale for Children, Integrated: Technical and Interpretive Manual: Harcourt Brace and Company, 2004.
    1. Wechsler D. WISC-V. NCS Pearson: Incorporated, 2014.
    1. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–76. 10.1093/schbul/13.2.261
    1. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). The British Journal of Psychiatry 1989.
    1. Robert CC, Thomas RP, Dragan MS, et al. . TheTemperament and Character Inventory (TCI): A guide to its developmentand use. 1994.
    1. Pélissolo A, Veysseyre O, Lépine JP. Validation of a computerized version of the temperament and character inventory (TCI) in psychiatric inpatients. Psychiatry Res 1997;72:195–9. 10.1016/S0165-1781(97)00099-1
    1. Baron-Cohen S, Wheelwright S, Skinner R, et al. . The autism-spectrum quotient (AQ): evidence from Asperger syndrome/high-functioning autism, males and females, scientists and mathematicians. J Autism Dev Disord 2001;31:5–17. 10.1023/A:1005653411471
    1. Petrovski S, Wang Q, Heinzen EL, et al. . Genic intolerance to functional variation and the interpretation of personal genomes. PLoS Genet 2013;9:e1003709 10.1371/journal.pgen.1003709
    1. Adzhubei IA, Schmidt S, Peshkin L, et al. . A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248–9. 10.1038/nmeth0410-248
    1. Richards S, Aziz N, Bale S, et al. . Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405–23. 10.1038/gim.2015.30
    1. Wechsler D. WAIS-III:Wechsler adult intelligence scale: Psychological Corporation, 1997.
    1. Grégoire J, Wierzbicki C. Comparaison de quatre formes abrégées de l’échelle d’intelligence de Wechsler pour adultes – troisième édition (WAIS-III). Revue Européenne de Psychologie Appliquée/European Review of Applied Psychology 2009;59:17–24. 10.1016/j.erap.2007.08.003
    1. Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Transl Res 2009;154:277–87. 10.1016/j.trsl.2009.09.005
    1. Bettens K, Sleegers K, Van Broeckhoven C. Genetic insights in Alzheimer’s disease. Lancet Neurol 2013;12:92–104. 10.1016/S1474-4422(12)70259-4
    1. Bayer TA, Falkai P, Maier W. Genetic and non-genetic vulnerability factors in schizophrenia: the basis of the "two hit hypothesis". J Psychiatr Res 1999;33:543–8. 10.1016/S0022-3956(99)00039-4

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir